Verona has announced the start of a Phase II clinical trial to evaluate a dry powder inhaler formulation of RPL554 in patients with moderate to severe chronic obstructive pulmonary disease.
Read More
London, UK-based Verona Pharma’s experimental phosphodiesterase therapy has hit targets in a mid-stage trial in patients with cystic fibrosis.
Read More
Patients have begun receiving Verona Pharma’s experimental respiratory drug RPL554 in a Phase IIb trial assessing its potential as a maintenance therapy for chronic obstructive pulmonary disease (COPD).
Read More
Verona Pharma has enrolled and dosed the first patient in a clinical study assessing its investigational drug RPL554 as a treatment for cystic fibrosis (CF).
Read More
